A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Rabusertib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Nov 2013 Planned End Date changed from 1 Nov 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 19 Aug 2013 Planned end date changed from 1 Aug 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov record.